HOME >> BIOLOGY >> NEWS
Taking the next step toward growing our own fuel

URBANA -- Developing a petroleum-free fuel from corn byproducts is one of the goals of a newly named research theme at the University of Illinois at Urbana-Champaign. Eight research laboratories will pool their expertise, attacking the problems from different directions to improve the efficiency of bioconversion of plant fibers into fuels and other value added products.

The new theme is the seventh to be chosen for the Institute for Genomic Biology under the direction of Harris A. Lewin, Gutgsell Endowed Chair in the department of animal sciences. Although the building housing the IGB will not be completed until 2006, the work that will go on inside already has begun.

Lewin said that the new IGB research theme, led by Hans Blaschek, will address one of the most critical problems facing our nation.

"With crude oil at $50 per barrel, we must examine renewal sources of energy as a viable alternative to fossil fuels," Lewin said. "The vision and experience of Blaschek and his co-workers will be important in setting the national agenda for future research on renewable energy sources. Importantly, the outcomes of this research may have direct benefit to farmers and the agricultural industries of the Midwest. I am proud to have the new theme on Molecular Bioengineering of Biomass Conversion as part of the IGB's research, education and economic development portfolio."

Blaschek is a microbiologist in the College of Agricultural, Consumer and Environmental Sciences. He has been studying microorganisms that are used in fermentation processes for over 20 years. He is striving to overcome the obstacles related to biomass conversion into value-added products.

"The beneficiaries of this research will be agriculture and agriculture-based industries in Illinois," Blaschek said, "but ultimately all of us will benefit as consumers of energy." He believes that renewable fuel made from corn is the direction we need to go in order
'"/>

Contact: Debra Levey Larson
dlarson@uiuc.edu
217-244-2880
University of Illinois at Urbana-Champaign
7-Oct-2004


Page: 1 2

Related biology news :

1. Taking a supplement of glycine helps prevent degenerative diseases such as arthrosis or osteoporosis
2. Taking heart failure to the MAT1
3. Taking chips to the next level of gene hunting
4. Vax and Pax: Taking turns to build an eye
5. Taking evolutions temperature: Researchers pinpoint the energy it takes to make a species
6. Taking a bite out of a fellow worker helps wasps recruit new foragers
7. Taking a break from fractures: A closer look at vitamin D
8. Taking a flying jump
9. Taking the piste out of Alpine vegetation
10. Bursts of waves drive immune system soldiers toward invaders
11. A decisive step toward a cure for insulin dependent diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Taking the next step toward growing our own fuel

(Date:2/12/2015)... Feb. 12, 2015   MedNet Solutions , ... clinical study management systems, has recently bolstered its ... distinguishing iMedNet as the ... (CROs) and healthcare consultants.  Building on the Program,s ... referrals and numerous co-marketing opportunities), MedNet,s new and ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... website ( http://www.nxt-id.com/ ) as part of its 2015 ... The Company launched its new consumer website for Wocketwallet.com ... , CEO of NXT-ID said, "Our new corporate website ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
(Date:3/4/2015)... , March 4, 2015 PDL BioPharma, Inc. (PDL) ... conversion rate for the: , 3.75% Convertible Senior ... shares of common stock per $1,000 principal amount or approximately ... conversion rate for the note is adjusted in connection with ... March 12, 2015, to all stockholders who own shares of PDL ...
(Date:3/4/2015)... , Mar. 04, 2015 Research and ... the addition of Jain PharmaBiotech,s new report ... their offering. This report follows ... characteristic that can be objectively measured and evaluated ... processes as well as pharmacological responses to a ...
(Date:3/4/2015)... , March 4, 2015 AcelRx Pharmaceuticals, ... pharmaceutical company focused on the development and commercialization ... and breakthrough pain, today announced that it will ... after market close on Monday, March 9th, 2015. ... at 4:30 p.m. Eastern Time (1:30 p.m. Pacific ...
(Date:3/4/2015)... PARIS , March 4, 2015 ... Hopitaux de Paris en ... «   SARAH   », qui compare   ... l,yttrium-90 avec le   sorafénib dans le carcinome ... atteints d,un cancer du foie avancé   ; ...
Breaking Biology Technology:PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6
Cached News: